Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANIK 
Anika Therapeutics Inc (ANIK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ANIK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.33
1 Year Target Price $21.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.21% | Avg. Invested days 59 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 153.67M USD | Price to earnings Ratio - | 1Y Target Price 21.33 |
Price to earnings Ratio - | 1Y Target Price 21.33 | ||
Volume (30-day avg) 3 | Beta 0.65 | 52 Weeks Range 10.47 - 29.11 | Updated Date 06/30/2025 |
52 Weeks Range 10.47 - 29.11 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -48.48% | Operating Margin (TTM) -16.37% |
Management Effectiveness
Return on Assets (TTM) -1.73% | Return on Equity (TTM) -6.07% |
Valuation
Trailing PE - | Forward PE 19.12 | Enterprise Value 125877761 | Price to Sales(TTM) 1.31 |
Enterprise Value 125877761 | Price to Sales(TTM) 1.31 | ||
Enterprise Value to Revenue 1.08 | Enterprise Value to EBITDA 163.48 | Shares Outstanding 14341400 | Shares Floating 10280506 |
Shares Outstanding 14341400 | Shares Floating 10280506 | ||
Percent Insiders 4.91 | Percent Institutions 90.28 |
Analyst Ratings
Rating 2 | Target Price 21.33 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anika Therapeutics Inc
Company Overview
History and Background
Anika Therapeutics Inc. was founded in 1992. It focuses on developing, manufacturing, and commercializing therapeutic products based on hyaluronic acid (HA) technology for tissue protection, healing, and repair.
Core Business Areas
- Joint Health: Viscosupplementation products like MONOVISC and ORTHOVISC for osteoarthritis pain relief.
- Early Intervention: Products focused on pain management and tissue regeneration in early stages of osteoarthritis and related conditions.
- Sports Medicine: Products for soft tissue repair and regenerative solutions for sports-related injuries.
- Regenerative Solutions: Products related to cell therapy and healing of damaged tissue.
Leadership and Structure
The leadership team includes Cheryl R. Blanchard, Ph.D. (President and CEO). The company has a typical corporate structure with departments such as R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- MONOVISC: A single-injection viscosupplement for osteoarthritis knee pain. Competitors include products from Sanofi (SYNVISC), Zimmer Biomet (Gel-One), and Seikagaku (ARTZ). Market share data unavailable without subscription services. Sales data not publicly available on a per-product basis, only total revenue is announced.
- ORTHOVISC: A multi-injection viscosupplement for osteoarthritis knee pain. Competitors include products from Sanofi (SYNVISC), Zimmer Biomet (Gel-One), and Seikagaku (ARTZ). Market share data unavailable without subscription services. Sales data not publicly available on a per-product basis, only total revenue is announced.
- HYALOFAST: Hyaluronic acid-based scaffold for cartilage regeneration. Competitors include Smith+Nephew. Market share data unavailable without subscription services. Sales data not publicly available on a per-product basis, only total revenue is announced.
Market Dynamics
Industry Overview
The orthopedic and regenerative medicine market is growing due to aging populations, increasing sports injuries, and demand for minimally invasive procedures.
Positioning
Anika is positioned as a specialty orthopedic company focusing on HA-based therapies with a portfolio of branded products. Competitive advantage lies in its HA technology and established presence in viscosupplementation.
Total Addressable Market (TAM)
The TAM for osteoarthritis treatment and regenerative medicine is estimated in the billions of dollars annually. Anika is positioned to capture a portion of this market through its existing product portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary HA Technology
- Established Brand Recognition (MONOVISC, ORTHOVISC)
- Focus on Specialty Orthopedics
- Distribution Network
Weaknesses
- Reliance on Viscosupplementation Market
- Limited Product Diversification
- Competition from Larger Players
- Dependence on Reimbursement Policies
Opportunities
- Expansion into New Geographies
- Development of Novel HA-based Therapies
- Acquisitions of Complementary Technologies
- Partnerships with Larger Orthopedic Companies
Threats
- Pricing Pressure from Competitors
- Changes in Reimbursement Policies
- Emergence of New Treatment Modalities
- Product Liability Litigation
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- ZBH (Zimmer Biomet)
- JNJ (Johnson & Johnson)
Competitive Landscape
Anika competes with larger orthopedic companies and specialized viscosupplementation providers. Its competitive advantage lies in its HA technology and focus, but it faces challenges from larger companies with greater resources.
Major Acquisitions
Parcus Medical, LLC
- Year: 2019
- Acquisition Price (USD millions): 26
- Strategic Rationale: Expanded Anika's sports medicine portfolio with soft tissue fixation and sports medicine products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trajectory not available without real-time data feed.
Future Projections: Future projections unavailable without access to proprietary analyst reports.
Recent Initiatives: Recent initiatives not available without access to real-time data feed.
Summary
Anika Therapeutics is a specialty orthopedic company with established products in viscosupplementation. Its strength lies in its HA technology, however, it faces competition from larger, more diversified players. Future growth depends on expanding its product portfolio and geographical reach, and mitigating threats from changing reimbursement policies and emerging technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports (General)
- Analyst Reports (General)
Disclaimers:
This analysis is based on publicly available information and general market knowledge. Actual financial data and market share figures may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 288 | Website https://www.anika.com |
Full time employees 288 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.